Empiric use of systemic antibiotics has reduced the
|
|
- Matthew Morgan
- 6 years ago
- Views:
Transcription
1 A Randomized Comparison of with as Empiric Anti-Fungal Agents in Cancer Patients with Prolonged Fever and Neutropenia Imtiaz A. Malik, MD, Imran Moid, MBBS, Zeba Aziz, MD, Shireen Khan, MBBS, Mohammad Suleman, MBBS PURPOSE: Several studies have documented the efficacy of amphotericin B as empiric antifungal therapy in cancer patients with prolonged fever and neutropenia. Amphotericin, however, is a toxic drug. has broad-spectrum antifungal activity with an excellent safety profile. Although prophylactic use of fluconazole is widespread, its efficacy as an empiric antifungal agent has not been extensively investigated. PATIENTS AND METHODS: We randomly assigned 106 patients with absolute neutropenia ( 500 cells L) and persistent fever of undetermined origin ( 38 C) despite 1 week of broadspectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0.5 mg/kg/day. Patients with obvious invasive fungal infections were excluded, as were those with abnormal renal or hepatic function. Success was defined as defervescence with the initially assigned antifungal regimen without development of clinically evident invasive fungal infection. RESULTS: Six patients were excluded from the analysis, mostly because they did not have severe neutropenia. Forty-eight patients received amphotericin B, and 52 received fluconazole. Baseline clinical characteristics and laboratory parameters as well as duration of neutropenia (7.7 versus 6.9 days), duration of fever (7.8 versus 8.1 days), and duration of hospitalization (10.4 versus 8.3 days) were similar between those receiving amphotericin and fluconazole. Treatment success rates and mortality rates were similar in the two groups: 22 (46%) patients in the amphotericin group and 29 (56%) patients in the fluconazole group responded successfully to therapy (P 0.3), whereas 16 (33%) patients in the amphotericin group and 14 (27%) patients in the fluconazole group died during hospitalization (P 0.5). Adverse events such as chills and fever (4 versus 1), bronchospasm (2 versus none), severe hypokalemia (25 versus 12) and nephrotoxicity (9 versus 3) were more frequently observed in patients receiving amphotericin. Adverse prognostic factors included prolonged duration of neutropenia and pneumonia. CONCLUSIONS: These results suggest that fluconazole is an equally effective but less toxic alternative to amphotericin B as empiric antifungal therapy in cancer patients with prolonged fever and neutropenia. Am J Med. 1998;105: by Excerpta Medica, Inc. From the Department of Medical Oncology, National Cancer Institute, Karachi (IAM, IM), Department of Oncology, Shaikh Zaid Hospital, Lahore (ZA), and Pfizer Laboratories Limited, Karachi (SK, MS), Pakistan. Requests for reprints should be addressed to Imtiaz A. Malik, MD, National Cancer Institute, 28-C, Tauheed Commercial Area, 26 Street, DHA-5, Karachi, Pakistan. Manuscript submitted July 21, 1997, and accepted in revised form July 14, Empiric use of systemic antibiotics has reduced the morbidity and mortality associated with febrile neutropenia (1 3). Patients with prolonged neutropenia, however, remain at a risk of persistent or recurrent fever. In patients without any other obvious cause, occult fungal infections are the most likely source of fever (4 7). Patients with fungemia or invasive fungal infection who remain neutropenic have extremely poor outcomes (8). Often this poor survival is attributable to delayed diagnosis. For example, only 25% to 40% of patients with disseminated candidiasis have positive blood cultures. Furthermore, inability to perform biopsies or other invasive diagnostic procedures in patients with bleeding diathesis and the lack of reliable serologic tests make early diagnosis difficult (9 12). Persistent or recurrent fever in a neutropenic patient being treated with broad-spectrum antibiotics may be the only clinical evidence of an invasive fungal infection. Difficulty in diagnosis, and the poor outcome of those with established fungal infection, have led to the empiric use of antifungal agents in patients with prolonged fever and neutropenia. Empiric therapy with amphotericin B results in defervescence, a reduction in subsequent fungal infections, and a concomitant decrease in mortality from infectious causes (13 16). Use of amphotericin B, however, is complicated by a high incidence of potentially serious side effects (17,18). Most patients develop chills and fever that can only be partially controlled with premedication. More serious consequences are the development of renal dysfunction and electrolyte imbalance. has broad-spectrum antifungal activity (19 22). Favorable pharmacokinetics, a good safety profile, reliable absorption from the gastrointestinal tract, by Excerpta Medica, Inc /98/$19.00 All rights reserved. PII S (98)00326-X
2 Comparison of with /Malik et al and availability in oral and parenteral formulations make fluconazole an attractive antifungal agent. It has proven efficacy against Cryptococcus neoformans and several candida species and has been used with variable success against blastomycosis, histoplasmosis, sporotrichosis, and coccidioidomycosis (23). It has, however, no substantial activity against aspergillus. has been used to treat patients with oro-pharyngeal and esophageal candidiasis, cryptococcal meningitis, and chronic disseminated candidiasis (24 26). is an equally effective but less toxic alternative to amphotericin B in nonneutropenic patients with candidemia (27). Prophylactic use of fluconazole prevents colonization and development of superficial infection with candida in patients with leukemia and reduces the incidence of both systemic and superficial fungal infections in those undergoing bone marrow transplantation (28 30). Bodey et al (31) have recently demonstrated that fluconazole is equally effective but less toxic than amphotericin B for prophylaxis in patients with leukemia. Serious side effects with the use of fluconazole are rare and limited to nausea, vomiting, anorexia, rash, and mild elevation of hepatic enzyme levels. We conducted a randomized trial to compare the efficacy and toxicity of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. PATIENTS AND METHODS Patient Eligibility This study was confined to adult cancer patients ( 16 years of age) with an absolute neutrophil count of 500/ L; persistent fever of 38 C or greater for 48 hours or more; at least 7 days of appropriate broad-spectrum antibiotic therapy (most often ceftazidime plus amikacin); and absence of any obvious source of fever, such as resistant bacterial infection, abscess, or infection with atypical microorganisms. Patients with known intolerance to the study drugs, evidence of systemic fungal infection, preexisting renal insufficiency (serum creatinine level 2.5 mg/dl), hepatic insufficiency (serum transaminase levels 4 times upper limit of normal or serum bilirubin level 3 mg/dl), or with recurrent fever of undetermined etiology were excluded. Pregnant or lactating women or patients who had used systemic antifungal drugs within the previous 14 days were also excluded. Informed consent was obtained from all patients, and the study was approved by the Institutional Human Subjects Committee. This study was carried out at two institutions. Study Design Patients with fever and neutropenia despite prolonged ( 7 days) use of broad-spectrum antibacterial therapy and without any evident source of infection were randomly assigned to receive either fluconazole 400 mg orally per day or amphotericin B 0.5 mg/kg/day. In patients with severe mucositis or diarrhea, fluconazole was given intravenously in the same dosage. These drugs were planned to be given for a minimum of 4 days and, if successful, to be continued until neutropenia recovered or the patient remained afebrile for 4 days without any evidence of systemic fungal infection. Patients were maintained on the same dose of amphotericin B unless they developed fungemia or systemic fungal infection. In that case, amphotericin dose was increased to 1 or 1.5 mg/kg/day. Saline loading was not routinely done unless patients developed nephrotoxicity. During the study period, patients were continued on broad-spectrum antibiotics, and changes were made as required. No other antifungal therapy was administered. Pretreatment requirements and follow-up during the study period: A complete history was obtained and physical examination was performed in all patients with particular attention to potential causes of fever. Complete blood counts, serum transaminase, creatinine and electrolyte levels were obtained. Throat, urine, stool, and at least 2 sets of blood cultures, including fungal cultures, were obtained in all patients. Cultures from other sites that appeared to be the cause of fever and fine needle aspiration of suspected areas were also carried out. Chest radiographs were taken. During therapy, temperature was determined every 4 hours and physical examination was performed at least once daily. Blood cultures were drawn, at least every other day, in patients who remained febrile. Similarly, repeat urine, throat, stool, and other cultures were taken at regular intervals. Laboratory tests were repeated on a daily basis or at least every other day. Patients were kept in strict reverse isolation, and fresh unpeeled fruits and vegetables were avoided. Response to therapy and evaluation of adverse events: The endpoint of therapy in this study was defervescence (oral temperature of 37.6 C or less throughout the remaining period of neutropenia). Time to defervescence was documented in all patients. Every attempt was made to determine the underlying cause of fever and categorize it as clinical or microbiologic infection versus fever of undetermined origin. Response to therapy was described as successful when defervescence occurred with the initially assigned regimen without development of systemic fungal infection throughout the study period. Patients who had no change in fever pattern, developed signs and symptoms of systemic mycosis, developed serious side effects that required discontinuation of therapy, or died from any cause during the study period were considered as failures. Whenever possible, the single most likely cause of death was determined. All adverse events were recorded, including time, severity, most likely cause, and outcome. Nephrotoxicity December 1998 THE AMERICAN JOURNAL OF MEDICINE Volume
3 Comparison of with /Malik et al Table 1. Clinical Characteristics of the Evaluable Patients at Enrollment*, (n 52), P Value Male sex 33 (69%) 32 (61%) 0.4 Age (years) Underlying disorders Leukemia 31 (65%) 28 (54%) 0.3 Others 17 (35%) 24 (46%) Clinical features Clinically toxic 34 (71%) 31 (60%) 0.2 appearance Oral mucositis 14 (29%) 15 (29%) 0.9 Oral candidiasis 2 (4%) 8 (15%) 0.06 Hypotension 9 (19%) 10 (19%) 0.9 Dyspnea 17 (35%) 13 (25%) 0.3 Type of fever Persistent 39 (81%) 40 (77%) 0.6 Recurrent 9 (19%) 12 (23%) Absolute neutrophil count per L Hemoglobin (g/dl) Platelet count ( 10 3 / L) Creatinine (mg/dl) * Plus-minus values are mean SD. was defined as a rise in serum creatinine level of 0.5 mg/dl or more compared with the baseline value. Hepatic toxicity was defined as an increase in transaminase or alkaline phosphatase values more than twice the pretreatment level. Electrolyte imbalance was categorized as Table 2. Clinical Characteristics of Patients at Termination of Therapy Duration of antifungal therapy Duration of neutropenia postrandomization Duration of fever postrandomization Mean duration of hospitalization Fever of undetermined origin (n 52) P Value (54%) 29 (56%) 0.9 Table 3. Bacterial and Fungal Infection Isolates in Patients with Microbiological Infections Micro-organism (n 52) Bacterial isolates Pseudomonas 1 1 Enterococcus 1 0 E. coli 3 1 Acinetobacter 2 0 S. aureus 0 1 Fungal isolates Candida albicans 1 0 Aspergillus 3 1 Fusarium 0 1 correctable when replacement of electrolytes allowed continuation of therapy, or refractory when therapy had to be discontinued. Other toxicities, such as drug rash, were individually determined. In patients developing nephrotoxicity, appropriate dose modifications were made. Statistical Considerations Data were analyzed with chi-square and Fisher s exact tests or with Student s t test, as appropriate. All P values are two tailed. Multivariate associations were tested with logistic regression analyses. Time to defervescence was compared using Kaplan-Meier curves. Statistical significance was set at P RESULTS Clinical Characteristics of the Study Patients One hundred and six patients were enrolled in the study. Six patients were excluded from the analysis, four patients because their neutrophil count was 500/ L. Two patients, on further investigation, had history of allergy to amphotericin. Forty-eight patients received amphotericin B, and 52 received fluconazole. Baseline clinical characteristics, such as sex, age, underlying disorder, and clinical signs and symptoms, and laboratory values, were similar in the two groups (Table 1). At the time therapy was terminated, the duration of fever, neutropenia and antifungal therapy were similar in the two groups (Table 2). Patients treated with fluconazole had a slightly, but not significantly, shorter duration of hospitalization than those who received amphotericin. Overall, the cause of fever remained undetermined in almost half of the patients. Pneumonia with negative cultures was the predominant clinical infection. Several patients developed bacterial or fungal infections; however, there were no marked differences between the two groups (Table 3). 480 December 1998 THE AMERICAN JOURNAL OF MEDICINE Volume 105
4 Comparison of with /Malik et al Table 4. Response Rates and Survival Data Outcome (n 52) P Value Amphotericin Difference 95% Confidence Interval Number of successes (%) 22 (46%) 29 (56%) % 29% to 9% of deaths 16 (33%) 14 (27%) 0.5 6% 12% to 24% Cause of death Pneumonia Others 6 6 Response Rates and Survival Data Overall success was obtained in half of the patients (Table 4). Time to treatment failure was similar between the two groups (Figure 1). Death accounted for the majority of the failures, as 30% of the patients died during the study period, usually due to pneumonia and respiratory failure. Intracranial bleeding accounted for a small number of deaths. No significant differences were observed between the two groups. Toxicity of Therapy Chills and fever were frequently observed in patients receiving amphotericin. These symptoms were successfully treated with antipyretics, antihistamines, and when necessary, meperidine. No patient was withdrawn from the study for this reason. Two patients developed immediate hypersensitivity reaction (flushing, hypotension, bronchospasm) to amphotericin and had to be withdrawn from the study. Severe electrolyte imbalance, nephrotoxicity, and hepatotoxicity were more often observed in patients receiving amphotericin (Table 5). Thirty-two (67%) patients receiving amphotericin and 19 (36%) patients receiving fluconazole experienced adverse side effects. The difference between the percentage of patients with adverse side effects in the two groups of 31% is highly significant (95% confidence interval [CI] 12% 49%; P 0.01). Importance of Prognostic Factors Several clinical variables, including dyspnea at the time of randomization, persistent neutropenia, duration of antifungal therapy, radiologic evidence of pneumonia, and development of clinical or microbiologic cause of infection were associated with failure of therapy (Table 6). In a multivariable analysis, persistent neutropenia (odds ratio [OR] 19; 95% CI: ), and pneumonia (OR 16; 95% CI: ) were independent predictors of failure. DISCUSSION has a well defined role as an empiric antifungal agent in neutropenic febrile patients who are unresponsive to broad-spectrum antibiotic therapy (13 16). In this setting, it causes defervescence and reduces the subsequent development of invasive mycoses, as well as mortality from infectious causes. Most patients treated with amphotericin, however, develop side effects (17,18)., which has comparable antifungal activity in several clinical situations (30 33), has not been extensively investigated as an empiric antifungal agent. Our study suggests that fluconazole may be an equally effec- Table 5. Toxicity of Therapy Side Effects (n 52) Figure 1. Time to defervescence among patients treated with amphotericin B or fluconazole. There was no significant difference between the two groups (P 0.7). Allergic reactions Chills and fever 4 1 Rash 1 Bronchospasm 2 Hypokalemia Correctable hypokalemia 13 9 Refractory hypokalemia 12 3 Hepatotoxicity Hyperbilirubinemia 9 5 Nephrotoxicity 9 3 Extrapyramidal symptoms 1 Several patients in each drug group had more than one side effect. December 1998 THE AMERICAN JOURNAL OF MEDICINE Volume
5 Comparison of with /Malik et al Table 6. Effect of Clinical Variables on Outcome* Parameter Success (n 51), Failure (n 49), P Value Male sex 32 (63%) 33 (67%) 0.6 Age (years) Underlying diagnosis of 26 (51%) 33 (67%) 0.09 leukemia Toxic appearance 31 (61%) 34 (69%) 0.4 Oral mucositis 15 (29%) 14 (29%) 0.9 Hypotension 7 (14%) 12 (24%) 0.2 Dyspnea 10 (20%) 20 (41%) 0.02 Oral candidiasis 4 (8%) 6 (12%) 0.5 Type of fever Persistent 42 (82%) 37 (75%) 0.4 Recurrent 9 (18%) 12 (25%) Absolute neutrophil count per L Hemoglobin (g/dl) Platelet count ( per L) Serum creatinine (mg/dl) Persistent neutropenia 8 (16%) 38 (77%) Duration of antifungal therapy Duration of neutropenia prerandomization Duration of neutropenia postrandomization Type of therapy Amphotericin 22 (43%) 26 (53%) (57%) 23 (47%) Fever of unknown origin 38 (76%) 17 (35%) Radiologic evidence of pneumonia 6 (12%) 26 (53%) 0.01 * Plus-minus values are mean SD. tive and less toxic alternative to amphotericin B in these patients. However, the total number of study patients, and particularly the number who developed clinically evident fungal infection, were small. A recent study confirmed the efficacy of fluconazole in nonneutropenic patients with candidemia (27). Moreover, the prophylactic use of fluconazole in patients expected to have prolonged neutropenia reduces the incidence of both superficial and invasive candidiasis and decreases the number of deaths attributable to fungal infections (28 30). Prophylactic use of fluconazole, however, is complicated by increased colonization and infection with fluconazole-resistant strains of candida, such as C. krusei and Torulopsis glabrata (34 37). More widespread use of fluconazole can be expected to increase the magnitude of this problem. Restricting the use of fluconazole to those requiring empiric antifungal therapy may reduce the development of widespread resistance to this agent. We attempted to identify factors that were associated with poor outcome. Patients with dyspnea at the time of randomization had poor prognosis, probably because of impending pneumonia; subsequent analysis confirmed that pneumonia was an adverse prognostic factor. Persistent neutropenia was also identified as an important prognostic factor, as previously reported (8,9,10,38). Successful outcome with antifungal therapy is associated with recovery of the neutrophil count. A different therapeutic approach may be necessary in patients with adverse prognostic factors. One of the major concerns with the use of fluconazole, as compared to amphotericin, relates to its lack of activity against aspergillus. The incidence of aspergillosis varies widely between different institutions (38 40). In centers with a high incidence of aspergillus infection, extreme caution is required before undertaking such an approach. Another limitation of this trial was that we used an openlabel study design, because differences in the nature of study drugs made blinding difficult. However, every effort was made to apply similar criteria in determining therapeutic failure. In conclusion, our study suggests that fluconazole is an equally effective but less toxic alternative to amphotericin B for empiric antifungal therapy of cancer patients with prolonged febrile neutropenia. If confirmed by other investigators, this approach may be more cost-effective than prophylactic use of fluconazole with the additional benefit of reduced chances of colonization and infection with the resistant organisms. ACKNOWLEDGMENT We are grateful to Mr. Hamad Yousuf for typing the manuscript. REFERENCES 1. Klastersky J. Concept of empiric therapy with antibiotic combinations. Am J Med. 1986;80(suppl 5C): Rubin RH. Empiric antibacterial therapy in granulocytopenia induced by cancer chemotherapy. Ann Intern Med. 1988;108: Pizzo PA. Management of fever in patients with cancer and treatment induce neutropenia. NEJM. 1993;328: Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis. 1966;19: Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients. Cancer. 1978;41: Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161: Donnelly JP, De Pauw BE. Current infectious complications and their management in acute leukemia and bone marrow transplantation. Int J Anti-Microb Agents. 1994;3: December 1998 THE AMERICAN JOURNAL OF MEDICINE Volume 105
6 Comparison of with /Malik et al 8. Maksymiuk AN, Thongprasert S, Hopfer R, Luna M, Fainstein V, Bodey GP. Systemic candidiasis in cancer patients. Am J Med. 1984; 77(suppl 40): Meunier-Carpentier F. Fungemia in the immunocompromised host. Am J Med. 1981;71: Degregorio MW, Lee W, Linker C, et al. Fungal infections in patients with acute leukemia. Am J Med. 1982;73: Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992; 14(suppl 1):S43 S Rinaldi MG. Problems in the diagnosis of invasive fungal diseases. Rev Infect Dis. 1991;13: Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1981;71: EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86: Karp JE, Merz WG, Charache P. Response to empiric amphotericin B during antileukemic therapy-induced granulocytopenia. Rev Infect Dis. 1991;13: Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis. 1991;13: Miller R, Bates JH. toxicity. A follow up report of 53 patients. Ann Intern Med. 1969;71: Moyer RD. Current role of therapy with amphotericin B. Clin Infect Dis. 1992;4(suppl): Galgiani JN., a new antifungal agent. Ann Intern Med. 1990;113: Grant SM, Clissod SP.. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39: Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990; 12(suppl 3):S318 S Kowalsky SF, Dixon DM. : a new antifungal agent. Clin Pharm. 1991;10: Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis. 1989;12:239S 247S. 24. Meunier F. treatment of fungal infections in immunocompromised host. Semin Oncol. 1990;17(suppl 6): Conti DJ, Tolkoff-Rubin NE, Baker GP Jr, et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation. 1989;48: Anaissie E, Bodey GP, Kantarjian H, et al. therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med. 1991;91: Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. NEJM. 1994;331: Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. NEJM. 1992;326: Winston DJ, Chandrasekar PH, Lazarus HM, et al. prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled double-blind, multicenter trial. Ann Intern Med. 1993;118: Uzun O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood. 1995;86: Bodey GP, Anaissie EJ, Elting LS, Estey E, O Brien S, Kantarjian HS. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer. 1994;73: Saag MS, Powderly WG, Cloud GA, et al. Comparisons of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. NEJM. 1992;326: Rozenberg-Arsaka M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of, fungal infections in patients with acute leukemia. J Antimicrob Chemother. 1991;27: Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. NEJM. 1991;325: Tam JY, Blume KG, Trober CG. Prophylactic fluconazole and candida krusei infections. NEJM. 1992;326: Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37: Rex JH, Rinaldi MG, Pfaller MA. Resistance of candida species to fluconazole. Antimicrob Agents Chemother. 1995;39: Saral R. Canadida and Aspergillus infections in immunocompromised patients: a overview. Rev Infect Dis. 1991;13: Hotchi RH, Okada M, Nasu T. Present state of fungal infections in autopsy cases in Japan. Am J Clin Pathol. 1980;74: Bodey G, Bueltmann B, Daguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbial Infect Dis. 1992;11: December 1998 THE AMERICAN JOURNAL OF MEDICINE Volume
Invasive fungal infections have become an increasing
A Multicenter, Randomized Trial of Fluconazole versus Amphotericin B for Empiric Antifungal Therapy of Febrile Neutropenic Patients with Cancer* Drew J. Winston, MD, James W. Hathorn, MD, Mindy G. Schuster,
More informationAmphotericin B or Ketoconazole Therapy of Fungal Infections in Neutropenic Cancer Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1987, p. 11-15 0066-4804/87/010011-05$02.00/0 Copyright 1987, American Society for Microbiology Vol. 31, No. 1 or Therapy of Fungal Infections in Neutropenic
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationMicafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia
ORIGINAL ARTICLE Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia Masamitsu Yanada 1,2, Hitoshi Kiyoi 2, Makoto Murata 1, Momoko Suzuki 1,
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationAntifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary?
ORIGINAL ARTICLE Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary? Christian En Delden', Daniel l? Lew', Bernard Chapuis2, Peter Rohner' and Bernard Hirschel'
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationCLINICAL ARTICLES. Methods. Patient Population. Inclusion Criteria
964 CLINICAL ARTICLES Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the Literature Elias J. Anaissie,
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationHepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications
375 Hepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications Veli-Jukka Anttila, Erkki Elonen, Stig Nordling, From the Department of Medicine, Divisions of Hematology
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationEvaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B
EXPERIMENTAL AND THERAPEUTIC MEDICINE 7: 941-946, 2014 Evaluation of hypokalemia and potassium supplementation during administration of liposomal amphotericin B EISEKI USAMI 1, MICHIO KIMURA 1, TETSUFUMI
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationAmphotericin B Lipid Complex (Abelcet ) 05/06
Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationThe sensitivity of fungal microorganisms to fluconazole is as follows:
FLUCAN Composition Each capsule contains Fluconazole 50, 100 or 150 mg Capsules Action Fluconazole is a triazole anti-fungal, which in sensitive fungi, inhibits cytochrome P450-dependent enzymes resulting
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationGJ Timmers 1, S Zweegman 1, AM Simoons-Smit 2, AC van Loenen 3, D Touw 3 and PC Huijgens 1. Summary:
(2000) 25, 879 884 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationdevelop invasive fungal infections. 1 4 The diagnosis of fungal infections is particularly difficult in immunocompromised
Bone Marrow Transplantation, (1997) 20, 39 43 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections
More informationScottish Medicines Consortium
Scottish Medicines Consortium anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 09 May 2008 The Scottish Medicines Consortium (SMC) has
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 VFEND 50 mg, film-coated tablets B/28 (CIP: 3592886) B/56 (CIP: 3592892) VFEND 200 mg, film-coated
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationPekka Riikonen. Introduction
Recombinant Human Granulocyte-Macrophage Colony-S timulating Factor in Combination with Antibiotics in the Treatment of Febrile Neutropenia in Children Pekka Riikonen Kuopio University Hospital, Division
More informationInfections in Oncology
Infections in Oncology Early Empiric Antibiotic Therapy for Febrile Neutropenia Patients at Low Risk Kenneth V. I. Rolston, MD, Edward B. Rubenstein, MD, of The University of Texas M.D. Anderson Cancer
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationCurrent Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationChanges in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever
Original Article Changes in Etiologic Microorganisms in Thai Patients with Chemotherapy-Induced Neutropenia and Fever Chonticha Auesomwang MD 1, Bundarika Suwannawiboon MD 2, Methee Chayakulkeeree MD,
More informationCurrent and Emerging Azole Antifungal Agents
CLINICAL MICROBIOLOGY REVIEWS, Jan. 1999, p. 40 79 Vol. 12, No. 1 0893-8512/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Current and Emerging Azole Antifungal Agents
More informationAmphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis
635 Amphotericin B Colloidal Dispersion vs. Amphotericin B as Therapy for Invasive Aspergillosis Mary H. White, Elias J. Anaissie, Shimon Kusne, John R. Wingard, John W. Hiemenz, Alan Cantor, Marc Gurwith,
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationPRODUCT MONOGRAPH. Caspofungin for Injection. 50 mg/vial, 70 mg/vial. Caspofungin (as caspofungin acetate) Antifungal
PRODUCT MONOGRAPH Pr. Caspofungin for Injection 50 mg/vial, 70 mg/vial Caspofungin (as caspofungin acetate) Antifungal MDA inc. 206-2401 Bristol Circle Oakville, ON L6H 5S9 Date of Preparation: January
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationSCIENTIFIC DISCUSSION
London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14855
More informationCANCIDAS PRODUCT MONOGRAPH. Caspofungin for injection, 50 mg/vial, 70 mg/vial (as caspofungin actetate) Antifungal. Date of Revision: April 28, 2017
PRODUCT MONOGRAPH Caspofungin for injection, 50 mg/vial, 70 mg/vial (as caspofungin actetate) Antifungal Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC Canada H9H 4M7 www.merck.ca Date of Revision:
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationSafety and tolerability of caspofungin acetate in the treatment of fungal infections
C.A. Sable B-Y T. Nguyen J.A. Chodakewitz M.J. DiNubile Safety and tolerability of caspofungin acetate in the treatment of fungal infections Key words: caspofungin; echinocandin; esophageal candiasis;
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationHigh risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient
More informationEmpiric Antimicrobial Therapy in Cancer Patients *
Haematology and Blood Transfusion Vol. 29 Modem Trends in Human Leukemia VI Edited by Neth, Gallo, Greaves, Janka Springer-Verlag Berlin Heidelberg 1985 Empiric Antimicrobial Therapy in Cancer Patients
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationOpen Forum Infectious Diseases Advance Access published February 11, 2016
Open Forum Infectious Diseases Advance Access published February 11, 2016 1 A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis Michael S. Abers 1,2, Musie
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationRisks and outcome of fungal infection in neutropenic children with hematologic diseases
The Turkish Journal of Pediatrics 2010; 52: 121-125 Original Risks and outcome of fungal infection in neutropenic children with hematologic diseases Selin Aytaç 1, İnci Yıldırım², Mehmet Ceyhan², Mualla
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationTransfusion Reactions
Transfusion Reactions From A to T Provincial Blood Coordinating Program Daphne Osborne MN PANC (C) RN We want you to know Definition Appropriate actions Classification Complete case studies Transfusion
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this
More informationOliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research
Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationLack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia
Lack of benefit of Granulocyte Macrophage or Granulocyte Colony Stimulating Factor in Patients with Febrile Neutropenia T. Siddiqui,I. A. Burney,A. Salam ( Departments of Medicine, The Aga Khan University
More informationFLUCAND HIKMA PHARMACEUTICALS
09-15 FLUCAND HIKMA PHARMACEUTICALS (Fluconazole) Description Flucand is a crystalline white - whitish powder, which is slightly soluble in water and in a saline solution. Its molecular weight is 306.3.
More informationASPERGILLOSIS IN THE NON-NEUTROPENIC HOST
ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction
More information